A New Study Evaluating the Activity of Modular CAR T for mYeloma

This study is testing a new type of CAR-T cell therapy called "modular CAR-T" for people with multiple myeloma — a blood cancer affecting plasma cells — whose disease has relapsed or stopped responding to multiple previous treatments. CAR-T therapy takes the patient's own immune cells, reprograms them in a lab, and infuses them back to fight the cancer. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory multiple myeloma - You have received at least 3 prior lines of therapy (including a proteasome inhibitor, an IMiD drug, and an anti-CD38 antibody) - Your cancer is producing measurable levels of myeloma protein - Your disease is refractory to your most recent treatment - You have had or are ineligible for a stem cell transplant **You may NOT be eligible if...** - You have not received enough prior lines of therapy - Your cancer is not producing measurable myeloma protein - Your overall health does not meet the fitness criteria for cell therapy Talk to your doctor to see if this trial is right for you.